2025年2月20日，英国伦敦GSK办公室大厅的标识。路透社/Chris J. Ratcliffe/档案照片 购买授权 公司 GSK plc 10月9日 - 宾夕法尼亚州州长Josh Shapiro办公室周五表示，GSK将投资超过8亿美元，扩建其位于宾夕法尼亚州Upper Merion的工厂，建设新的生物制药制造和研究中心，未来五年内创造超过300个就业岗位。
Signage is pictured in the main lobby of GSK offices in London, Britain, February 20, 2025. Companies GSK plc Oct 9 - GSK will invest more than $800 million to expand its Upper Merion, Pennsylvania site into a new biopharmaceutical manufacturing and research hub, creating more than 300 jobs over the next five years, Pennsylvania Governor Josh Shapiro's office said on Friday.
该投资将在蒙哥马利县建立一个集药物制造、研发、质量检测和数字化运营于一体的基地。
The investment will establish a site that combines drug manufacturing, research and development, quality testing and digital operations in Montgomery County.
GSK表示，建设计划于2027年开始，该项目将支持生物制剂的临床和商业化生产。
GSK said construction is planned to begin in 2027 and the project will support both clinical and commercial production of biologic medicines.
预计该扩建项目将创造超过300个新就业岗位，并保留宾夕法尼亚州约4,500个现有全职岗位。
The expansion is expected to create more than 300 new jobs and retain about 4,500 existing full-time jobs in Pennsylvania.
公司表示，该项目将包括一个新的商业规模生物制剂制造设施、一个研究中试工厂和一个集中质量控制实验室。
The company said the project will include a new commercial-scale biologics manufacturing facility, a research pilot plant and a centralized quality-control laboratory.
宾夕法尼亚州官员表示，GSK将有资格获得与该投资挂钩的州制造业税收激励。
Pennsylvania officials said GSK will be eligible for state manufacturing tax incentives tied to the investment.
根据州官员的说法，Upper Merion扩建项目和GSK此前宣布的兰开斯特县工厂项目合计代表了在宾夕法尼亚州近17亿美元的计划投资。
The Upper Merion expansion and GSK's previously announced Lancaster County facility project together represent nearly $1.7 billion of planned investment in Pennsylvania, according to state officials.
GSK（其美国总部位于费城）表示，此次扩建将有助于加速未来药物的开发和供应。
GSK, whose U.S. headquarters is in Philadelphia, said the expansion will help accelerate the development and supply of future medicines.